Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Rapamycin activates TGF receptor independently of its ligand: implications for endothelial dysfunction

Texto completo
Autor(es):
Miyakawa, Ayumi A. [1, 2, 3] ; Girao-Silva, Thais [3] ; Krieger, Jose E. [3] ; Edelman, Elazer R. [1, 2]
Número total de Autores: 4
Afiliação do(s) autor(es):
[1] Harvard Med Sch, Brigham & Womens Hosp, Cardiovasc Div, Dept Med, Boston, MA 02115 - USA
[2] MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 - USA
[3] HCFMUSP, InCor, Inst Heart, Lab Genet & Mol Cardiol, BR-054003 Sao Paulo, SP - Brazil
Número total de Afiliações: 3
Tipo de documento: Artigo Científico
Fonte: Clinical Science; v. 132, n. 4, p. 437-447, FEB 28 2018.
Citações Web of Science: 2
Resumo

Rapamycin, the macrolide immunosuppressant and active pharmaceutic in drug-eluting stents (DES), has a well-recognized antiproliferative action that involves inhibition of the mTOR pathway after binding to the cytosolic protein FKBP12. TGF receptor-type I (TGFRI) spontaneous activation is inhibited by the association with FKBP12. We hypothesized that rapamycin, in addition to inhibition of mTOR signaling, activates TGFRI independent of TGF beta. Human umbilical vein endothelial cells (HUVECs) were treated with rapamycin (10 nmol/l) and/or TGF beta RI kinase inhibitor (TGFRIi, 100 nmol/l) for 24 h. Rapamycin induced SMAD phosphorylation (SMAD1, SMAD2, and SMAD5) and PAI-1 up-regulation, which was specifically abrogated by SMAD2 knockdown. TGFRIi efficiently blocked phosphorylation of SMAD2, but not SMAD1/5. Interestingly, the inhibitor did not alter cell proliferation arrest induced by rapamycin. Active TGF beta secretion was not affected by the treatment. Neutralizing TGF beta experiments did not influence SMAD2 phosphorylation or PAI-1 expression indicating that activation of this pathway is independent of the ligand. In addition, rapamycin induction of endothelial-to-mesenchymal transition (EndMT) was potentiated by IL-1 beta and efficiently blocked by TGFRIi. In vivo, the prothrombogenic effects of rapamycin and up-regulation of PAI-1 inmurine carotid arteries were reduced by TGFRIi treatment. In conclusion, we provide evidence that rapamycin activates TGF receptor independent of its ligand TGF beta, in concert with promotion of PAI-1 expression and changes in endothelial phenotype. These undesirable effects, the prothrombogenic state, and activation of EndMT are SMAD2-dependent and independent of the therapeutic rapamycin-induced cell proliferation arrest. (AU)

Processo FAPESP: 14/06844-9 - Transição endotélio-mesenquimal durante o remodelamento da arterialização venosa: efeito do estiramento mecânico na plasticidade endotelial
Beneficiário:Thais Girão da Silva
Linha de fomento: Bolsas no Brasil - Doutorado
Processo FAPESP: 13/17368-0 - Genômica cardiovascular: mechanismos & novas terapias - CVGen mech2ther
Beneficiário:José Eduardo Krieger
Linha de fomento: Auxílio à Pesquisa - Temático